ActivSight Intraoperative Imaging Module for Enhanced Surgical Visualization Receives FDA Clearance

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

AAOS on IPO Elimination Reversal in 2022 CMS Outpatient Rule

AAOS is encouraged to hear that CMS has heeded the patient safety concerns of the physician community regarding the abrupt elimination of the Inpatient Only.

Stryker Steps up to the Plate at Chickasaw Bricktown Ballpark with Its SmartRobotics™ Technology

Stryker, the Official SmartRobotics™ Joint Replacement Partner of Minor League Baseball, showcases its Mako SmartRobotics™ Technology to Oklahoma City Dodgers fans.

April 9, 2021

ActivSight Intraoperative Imaging Module is for enhanced surgical visualization. The hardware agnostic imaging module has been designed to provide surgeons real-time intraoperative visual data and imaging not currently available to surgeons through existing technologies, helping to improve patient outcomes and safety in the operating room.

Receiving FDA 510(k) clearance for our ActivSight enhanced visualization module is a significant milestone in bringing Activ Surgical’s technology to operating rooms around the world,” said Todd Usen, CEO of Activ Surgical. “Given there is a $36 billion cost for preventable surgical errors, we believe ActivSight has the potential to make an immediate impact in the OR. We look forward to working closely with our initial pilot customers over the next several months to further validate ActivSight and revolutionize surgical care.”

ActivSight is the company’s proprietary hardware imaging module that will power its next product, ActivInsights. ActivInsights will be part of the ActivEdge™ software platform, which will use artificial intelligence (AI) and machine learning (ML) technology to produce surgical insights. The first ActivInsight that will be made available is perfusion insights, and will offer the ability to see blood flow and perfusion in real time, without the use of traditional dyes.

“My mission when I founded Activ Surgical in 2017 was to democratize surgical care by extending insights from experienced surgeons to all surgical systems, ensuring world class surgical care for everyone around the world,” said Dr. Peter Kim, Founder and CSMO, Activ Surgical. “The FDA clearance of our ActivSight enhanced visualization modules brings us one step closer to bringing this vision to fruition, in addition to improving patient safety and surgical outcomes for all.”

To date, 13 major healthcare systems around the world have committed to ActivSight‘s initial launch, which is planned for the second half of 2021.

spot_img

DON'T MISS

Dr. Woodrow Myers Joins the Freespira Board of Directors

Former Blue Cross Blue Shield Health Plan chief medical officer and chief healthcare strategist brings clinical, quality and business insights to fast-growing digital therapeutic company.

Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel

Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at Wyeth Pharmaceuticals (now part of Pfizer).

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.